Martin S. Tallman

Martin S. Tallman is a leading clinical investigator in acute myeloid leukemia and acute promyelocytic leukemia (APL), serving as Chief of the Leukemia Service at Memorial Sloan Kettering Cancer Center (MSKCC). His career has been defined by an unwavering commitment to rigorously designed clinical trials and by his pivotal contributions to establishing all-trans retinoic acid (ATRA) plus arsenic trioxide (ATO) as the curative standard of care for APL—a regimen that transformed a once-fatal subtype into one with cure rates exceeding 90%. Tallman has led or co-led some of the most influential cooperative group trials in AML conducted through ECOG-ACRIN and the Intergroup framework. His clinical research has encompassed induction intensification, post-remission consolidation strategies, allogeneic transplantation indications, and—more recently—the integration of targeted agents such as FLT3 inhibitors and IDH inhibitors into frontline and relapsed/refractory settings. He has also been a champion for developing risk-adapted approaches that spare low-risk patients the toxicity of intensive post-remission therapy while directing the most aggressive interventions to those with adverse features. As a senior mentor and educator, Tallman has trained dozens of leukemia clinicians who now lead programs nationwide. He is a past president of the American Society of Hematology (ASH) and has served on editorial boards and guideline committees for NCCN, ELN, and ASH, ensuring that evidence from trials reaches practicing hematologists in actionable formats. His institutional influence at MSKCC, combined with his national cooperative group leadership, positions him among the most impactful clinical trialists in hematologic malignancies.